Sibutramine use in pregnancy: Report of two cases

---

Atıf İçin Kopyala

Kadioglu M., ULKU C., YARIS F., Kesim M., Kalyoncu N. İ., Yaris E.

BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, cilt.70, sa.8, ss.545-546, 2004 (SCI-Expanded)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 70 Sayı: 8
• Basım Tarihi: 2004
• Doi Numarası: 10.1002/bdra.20052
• Dergi Adı: BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.545-546
• Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

BACKGROUND: Sibutramine is a drug used for the medical treatment of obesity. No data are available on sibutramine use in pregnancy. We report the fetal outcomes of two pregnant women exposed to sibutramine. CASES: The first woman was exposed to 10 mg/day of sibutramine during gestational weeks 4-6. The second woman was exposed to 10 mg/day of sibutramine during gestational weeks 5-8. At weeks 37 and 39, they delivered healthy infants. CONCLUSIONS: To our knowledge, this is the first report of sibutramine exposure in pregnancy. These cases may contribute to the knowledge about sibutramine use during pregnancy. (C) 2004 Wiley-Liss, Inc.